MeritValue

Glucose Health, Inc.

GLUCdata completeness 75%7 fiscal years on file

Data notes: no data for concept 'capex'; no data for concept 'epsDiluted'; no data for concept 'incomeTaxExpense'

The thesis, from the filings

Glucose Health, Inc. earns about -1798% on equity, and has bought back 63% of its shares over 5 years. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own
FigureFY 2012FY 2013FY 2014FY 2015FY 2016
Revenue—$2241$2,7392$4,2723$313,2293
Net income−$399,0784−$1.46M5−$669,4096−$266,0647−$410,4437
Operating cash flow−$83,6918−$131,9859−$135,35210−$115,77611−$39,26311
Capital expenditure—————
Free cash flow (derived)—————
Total debt—$78,71512$169,92312——
Cash & equivalents$1,07613$71114$4,87115$2,05515$20,54215
Diluted shares7.6M297,225675,1552.0M2.8M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$1.77
your share of equity
Profit it earned you last year
−$1.47
Free cash flow it threw off
—
Debt you’d be carrying
—

10 shares is a claim on −$1.77 of net worth that earned you −$1.47 last year.

iii. Is this a good business?
Moat signal · return on equity
-1798% avg · 5y
FY12 -1798%FY13 —FY14 —FY15 —FY16 —

It earned an average -1798% on equity over 5 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →
Management signal · capital allocation
−63% shares · 5y

Share count is down 63% over 5 years — management has been buying back stock, quietly handing owners a bigger slice. Total debt has risen 116% over the same window.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
only 0 years of FCF (need ≥3) — model not applicable
DCF · Growth Exit 5Y
not applicable
only 0 years of FCF (need ≥3) — model not applicable
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2013-12-31 · accession 0001477932-15-001981 (SalesRevenueGoodsNet)
  2. 10-K · period ending 2014-12-31 · accession 0001477932-16-009786 (SalesRevenueGoodsNet)
  3. 10-K · period ending 2015-12-31 · accession 0001477932-17-001354 (SalesRevenueGoodsNet)
  4. 10-K · period ending 2012-12-31 · accession 0001477932-14-003318 (NetIncomeLoss)
  5. 10-K · period ending 2013-12-31 · accession 0001477932-15-001981 (NetIncomeLoss)
  6. 10-K · period ending 2014-12-31 · accession 0001477932-16-009786 (NetIncomeLoss)
  7. 10-K · period ending 2015-12-31 · accession 0001477932-17-001354 (NetIncomeLoss)
  8. 10-K · period ending 2012-12-31 · accession 0001477932-14-003318 (NetCashProvidedByUsedInOperatingActivities)
  9. 10-K · period ending 2013-12-31 · accession 0001477932-15-001981 (NetCashProvidedByUsedInOperatingActivities)
  10. 10-K · period ending 2014-12-31 · accession 0001477932-16-009786 (NetCashProvidedByUsedInOperatingActivities)
  11. 10-K · period ending 2015-12-31 · accession 0001477932-17-001354 (NetCashProvidedByUsedInOperatingActivities)
  12. 10-K · period ending 2013-12-31 · accession 0001477932-15-001981 (DebtCurrent)
  13. 10-K · period ending 2012-12-31 · accession 0001477932-15-001981 (CashAndCashEquivalentsAtCarryingValue)
  14. 10-K · period ending 2013-12-31 · accession 0001477932-16-009786 (CashAndCashEquivalentsAtCarryingValue)
  15. 10-K · period ending 2014-12-31 · accession 0001477932-17-001354 (CashAndCashEquivalentsAtCarryingValue)